Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Ipsita Pal, PhD, Sohani Das Sharma, PhD, Andre M. Grilo, PhD, Prabhjot S. Mundi, MD, Luigi Scotto, PhD, Abdullah Mahmood Ali, PhD, Luke E Berchowitz, PhD, Siddhartha Mukherjee, MD PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 2864.

https://doi.org/10.1182/blood-2019-129528

Published: 2019

Journal Articles

Azacitidine and Romidepsin Synergize to Induce Expression of Cancer Testes Antigens (CTA) and Shift Peripheral T-Cell Lymphoma (PTCL) Cell Lines Toward a Th1-like Phenotype

Cristina Kinahan, BS, Luigi Scotto, PhD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2845.

https://doi.org/10.1182/blood-2018-99-117344

Published: 2018

Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 2809.

https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809

Published: 2017

Journal Articles

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

Luigi Scotto, PhD, Cristina Kinahan, B.S., Beatrice Casadei, MD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 2743.

https://doi.org/10.1182/blood.V130.Suppl_1.2743.2743

Published: 2017

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

Journal Articles

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Yun Hao, Nicholas P. Tatonetti, PhD, Michael Mangone, PhD, Shirong Li, PhD, Suzanne Lentzsch, Ronald B. Realubit, PhD, Charles Karan, Jr., PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 593.

https://doi.org/10.1182/blood.V126.23.593.593

Published: 2015

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Matko Kalac, MD PhD, Michael Mangone, PhD, Alison Rinderspacher, PhD, Shi-Xian Deng, PhD, Luigi Scotto, PhD, Jeremie Vendome, PhD, Mukesh Bansal, PhD, Andrea Califano, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 4435.

https://doi.org/10.1182/blood.V126.23.4435.4435

Published: 2015

Journal Articles

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Luigi Scotto, PhD, Xavier Jirau-Serrano, BS, Kelly Zullo, MS, Michael Mangone, PhD, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3703.

https://doi.org/10.1182/blood.V126.23.3703.3703

Published: 2015

Journal Articles

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Jennifer E Amengual, MD, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, BA, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, PhD, Ying Wei, Jimmy Duong, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3708.

https://doi.org/10.1182/blood.V126.23.3708.3708

Published: 2015

Journal Articles

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Kelly Zullo, MS, Yige Guo, PhD, Laurence Cooke, B.A., Xavier Jirau Serrano, BS, Michael Mangone, PhD, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Daruka Mahadevan, MD PhD, Owen A. O'Connor, MD PhD

Blood (2014) 124 (21): 4493.

https://doi.org/10.1182/blood.V124.21.4493.4493

Published: 2014

Journal Articles

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Changchun Deng, MD PhD, Mark Lipstein, B.S., Xavier Jirau Serrano, Michael Mangone, PhD, Luigi Scotto, PhD, Owen A O'Connor, MD, PhD, Peter Sportelli, Hari P. Miskin, MS, Srikant Viswanadha, PhD

Blood (2014) 124 (21): 1770.

https://doi.org/10.1182/blood.V124.21.1770.1770

Published: 2014

Journal Articles

The HDACi Romidepsin Markedly Synergizes With Inhibition Of ATM By KU60019 In Mantle Cell Lymphoma

Luigi Scotto, PhD, Kelly Zullo, BS, Xavier Jirau Serrano, BS, Laura K Fogli, MS, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 3066.

https://doi.org/10.1182/blood.V122.21.3066.3066

Published: 2013

Journal Articles

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Michael Mangone, PhD, Anna H Mei, BA, Luigi Scotto, PhD, Michele Visentin, PhD, Enrica Marchi, MD, PhD, I. David Goldman, MD, Constantine S. Mitsiades, MD, PhD, Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 4430.

https://doi.org/10.1182/blood.V122.21.4430.4430

Published: 2013

Journal Articles

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib

Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 5141.

https://doi.org/10.1182/blood.V122.21.5141.5141

Published: 2013

Journal Articles

The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma

Owen A. O'Connor, MD, PhD, Enrica Marchi, MD, PhD, Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Fabio Fuligni, Pier Luigi Zinzani, MD, Stefano A. Pileri, Pier Paolo Piccaluga, MD, PhD

Blood (2013) 122 (21): 646.

https://doi.org/10.1182/blood.V122.21.646.646

Published: 2013

Journal Articles

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Jennifer E. Amengual, MD, Paul M Johannet, Xavier Jirau-Serrano, BS, Kelly Zullo, BS, Daniela Hoehn, MD, PhD, Govind Bhagat, MD, Maximilian Lombardo, B.S., Luigi Scotto, PhD, Simon S Jones, PhD, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 648.

https://doi.org/10.1182/blood.V122.21.648.648

Published: 2013

Journal Articles

Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.

Salvia Jain, MD, Xavier Jirau-Serrano, BS, Carmine F Palermo, BS, Luigi Scotto, PhD, Kenneth P Olive, PhD, Govind Bhagat, MD, Serge Cremers, PhD, Jennifer E Amengual, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2758.

https://doi.org/10.1182/blood.V120.21.2758.2758

Published: 2012

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

NARROW

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Azacitidine and Romidepsin Synergize to Induce Expression of Cancer Testes Antigens (CTA) and Shift Peripheral T-Cell Lymphoma (PTCL) Cell Lines Toward a Th1-like Phenotype

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

The HDACi Romidepsin Markedly Synergizes With Inhibition Of ATM By KU60019 In Mantle Cell Lymphoma

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib

The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only